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Abstract
Background: Mycobacterium tuberculosis continues to be a major pathogen in the third world,
killing almost 2 million people a year by the most recent estimates. Even in industrialized countries,
the emergence of multi-drug resistant (MDR) strains of tuberculosis hails the need to develop
additional medications for treatment. Many of the drugs used for treatment of tuberculosis target
metabolic enzymes. Genome-scale models can be used for analysis, discovery, and as hypothesis
generating tools, which will hopefully assist the rational drug development process. These models
need to be able to assimilate data from large datasets and analyze them.
Results: We completed a bottom up reconstruction of the metabolic network of Mycobacterium
tuberculosis H37Rv. This functional in silico bacterium, iNJ661, contains 661 genes and 939 reactions
and can produce many of the complex compounds characteristic to tuberculosis, such as mycolic
acids and mycocerosates. We grew this bacterium in silico on various media, analyzed the model in
the context of multiple high-throughput data sets, and finally we analyzed the network in an
'unbiased' manner by calculating the Hard Coupled Reaction (HCR) sets, groups of reactions that
are forced to operate in unison due to mass conservation and connectivity constraints.
Conclusion: Although we observed growth rates comparable to experimental observations
(doubling times ranging from about 12 to 24 hours) in different media, comparisons of gene
essentiality with experimental data were less encouraging (generally about 55%). The reasons for
the often conflicting results were multi-fold, including gene expression variability under different
conditions and lack of complete biological knowledge. Some of the inconsistencies between in vitro
and in silico or in vivo and in silico results highlight specific loci that are worth further experimental
investigations. Finally, by considering the HCR sets in the context of known drug targets for
tuberculosis treatment we proposed new alternative, but equivalent drug targets.
Background
Tuberculosis continues to be a devastating pathogen
throughout the world, particularly in developing nations.
In 2001, the World Health Organization (WHO) esti-
mated 8.5 million new cases of tuberculosis (based on 3.8
million new reported cases) and an estimated 1.8 million
deaths from tuberculosis in 2000 [1]. Within the United
States, the number of reported cases of tuberculosis has
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trend reversed in 1986 and peaked in 1992 [2,3]. This
reversal has been attributed principally to HIV/AIDs,
immigration from countries with high prevalence of
tuberculosis, poverty, homelessness, and multi-drug
resistant (MDR) tuberculosis [1,2]. MDR tuberculosis is
generally defined as strains that are resistant to treatment
with isoniazid and rifampin [4], two of the key first line
antituberculosis drugs [1]. MDR strains of tuberculosis
emerged in the early 1990s and have now been found all
over the world [4].
Many of the unique properties of tuberculosis are attribut-
able to its metabolism, particularly the complex fatty acids
characteristics of the organism. These mycolic acids, phe-
nolic glycolipids, and mycoceric acids confer many of the
properties such as its acid-fastness and are believed to con-
tribute to the resilience of the organism. Mycobacterium
tuberculosis can survive in a wide range of environments
(many different tissues) and fairly extreme pHs [5]. One
of the most confounding factors with these bacteria is
their ability to survive for long periods of time in a dor-
mant stage. The slow doubling time of tuberculosis has
further limited the amount of experimental data that can
be generated. Many of the first and second line drugs used
to treat tuberculosis have metabolic targets, so developing
systems level models of metabolism are anticipated to be
of great use in the future.
DNA sequencing of the ~4.4 Mbp genome of Mycobacte-
rium tuberculosis H37Rv (M. tb) in 1998 [6] enabled the
ability the pursuit of genome-scale analyses of this micro-
organism. The remarkable relevance to world health and
disease control and the need to understand the metabolic
function of the organism all evoke the need of a genome-
scale metabolic model. Long-term anticipated goals and
applications of such models are to understand the growth
of mycobacteria under different conditions, identifying
strategies to improve growth in vitro (for experimental and
diagnostic purposes), and identifying new drug targets for
treatment.
In order to gain understanding about the unique charac-
teristics of this important pathogen, we manually recon-
structed the metabolic network of M. tb in silico (iNJ661),
from which we developed a model to compute perform
computational analyses and interpret experimental data.
These bottom-up reconstructions have been described in
the past as, biochemically, genetically and genomically
structured (BiGG) 'databases'. We employ constraint-
based reconstruction and analysis (COBRA) of this BiGG
reconstruction to learn about its normal metabolic func-
tion and to infer new potential targets for drugs.
Results and discussion
The reconstruction process has been described previously
[7,8], Figure 1 summarizes this process in brief. The net-
work statistics for iNJ661, which has 661 genes and 939
intra-system reactions, are summarized in Table 1. A bio-
mass objective function was defined using available meas-
urements of M. tb H37Rv and other mycobacteria strains
if information was lacking. The biomass objective func-
tion was defined using the literature for chemical compo-
sition studies of M. tb [9-13]. When such information was
not found for the specific strain, Mycobacterium bovis was
used (for example to approximate the biomass composi-
tion of nucleotides and peptidoglycans [14]). The simple
fatty acids compositions were based on studies of the
mycobacterial cell wall [15]. The biomass function
includes 90 metabolites in addition growth associated
maintenance ATP costs (see Table 2). [See Additional file
1] for more detailed information.
M. tb growth in silico
Flux Balance Analysis (FBA) was used to grow iNJ661 in
silico maximizing the biomass function defined in Table 2
(see Materials and Methods). iNJ661 was grown in silico
on three different types of media, Middlebrook 7H9 (sup-
plemented with glucose and glycerol) [16], Youmans
[17], and the chemically defined rich culture media
(CAMR) [18]. Uptake fluxes which define the different
media conditions are shown in Table 3 and the computed
results under the different conditions are summarized in
Table 4. The doubling times are within the range
described in the literature [18,19], and as expected, the
growth rates are higher with the richer media. The mini-
mum doubling time of 14.7/hr described by [18] are
within the capabilities of maximum growth of iNJ661.
As noted by Primm et al [20], M. tb growth on Middle-
brook 7H9 media requires supplementation with glucose
and glycerol. Glycerol is a component of the biomass
function (Table 2) according to the chemical composition
measurements performed by [14] on Mycobacterium
bovis. So in order to grow in silico, glycerol will either
need to be in the medium or the cell must have some way
of producing it from other precursors. iNJ661 was able to
grow when glucose uptake was abrogated, however, it
always required glycerol supplementation in the media
which could be due to the biomass requirement or due to
the need for glycerol for the production of a different
essential metabolite. The growth dependence on glycerol
and glucose uptake can be seen in the phase plane dia-
gram depicted in Figure 2a. In this figure, the biomass
objective function is optimized while the glucose and
glycerol uptake fluxes are varied in different combina-
tions. The resulting plot shows how the growth capability
of iNJ661 varies as a function of glucose and glycerol
uptake. The solid black lines depict isoclines, along whichPage 2 of 20
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ried out in order to understand the essentiality of glycerol
and non-essentiality of glucose in iNJ661. Since flux dis-
tributions calculated by FBA are non-unique, flux variabil-
ity analysis (see Methods) can be used to calculate the
span of each flux while still achieving the maximum value
for the objective function. Reactions with non-zero fluxes,
in which the maximum flux equals the minimum flux
(and is non-zero), are essential in achieving the particular
objective (no alternative pathways exist). Flux variability
[22] at maximum growth, with Middlebrook media with
glucose and glycerol supplementation (Table 2) was per-
formed in order to identify the constraining flux(es) that
prevents growth on glucose but not glycerol. The only
non-zero fluxes with no flexibility, directly involving the
metabolism of glycerol, were the glycerol transporter
(GLYCt) and glycerol kinase (Rv3696c, GlpK, GLYK). The
production of glycerol-3-phosphate via glycerol kinase is
essential for membrane and fatty acid metabolism involv-
ing fatty-acyl glycerol phosphates and interconversions
between CDP-diacyl-glycerol and phosphatidyl-glycerol
phosphates. These results are consistent and expected
given the importance of membrane metabolism in the
role of biomass production.
The non-zero fluxes with no flexibility directly involving
glucose were the glucose transporter (GLCabc, SugABC,
Rv1236+Rv1237+Rv1238) and glucokinase (PPGKr,
PpgK, Rv2702). Glucose-6-phosphate is subsequently
essential for a number of other reactions involving various
aspects of membrane metabolism, including the synthesis
of trehalose phosophate (TRE6PS, OtsA, Rv3490) and
inositol-phosphate (MI1PS, Ino1, Rv0046c), in addition
to phosphoglucomutase (PGMT, PgmA, Rv3068c). These
three reactions are required not only for optimal growth,
but they are in fact essential for any growth at all in silico.
Only one of these, however, has been suggested to be
essential experimentally (Rv3490) [23]. Growing iNJ661
in Middlebrook media (with glycerol but without glucose
supplementation) severely retards the growth rate, how-
ever it is still viable in silico in contrast to M. tb growth in
vitro. The discrepancy between in vitro essentiality of glu-
cose, but non-essentiality of reactions requiring glucose
derivatives and in silico non-essentiality of glucose suggest
that there may be non-metabolic functions related to the
need for glucose, in addition to alternative metabolic
pathways for the production and/or use of glucose-6-
phosphate.
Figure 2b characterizes the growth dependence on the
uptake rates of inorganic phosphate and sulfate. Limiting
uptake of either of these molecules will inhibit growth in
silico. Although the uptake fluxes are small compared to
the uptake of the carbon sources and oxygen, both are
required for growth of M. tb. Consequently, the sulfate
and phosphate transporters may serve as bacteriostatic
and possibly bacteriocidal drug targets. A robustness anal-
ysis (see Methods) was carried for biomass production by
iNJ661 for phosphate and sulfate [see Additional file 7].
This was compared to a robustness analysis performed for
the in silico E. coli strain iJR904 [24] on aerobic glucose
conditions [see Additional file 7]. The sensitivity of the
respective biomass production rates to the uptake fluxes
are given by the slopes of the plots for each organism. The
sensitivity to the phosphate uptake rate for iNJ661 and
iJR904 are both approximately 1. However, the slope for
sulfate uptake in iNJ661 is approximately four times that
of iJR904 (about 16 for iNJ661 compared to about 4 for
iJR904). This difference reflects the relatively larger
amount of sulfur as a percent of total biomass in M. tb
compared to E. coli, which is consistent with knowledge of
M. tb's composition [25]. Collectively, the phase planes
and robustness plots suggest that M. tb may be much more
sensitive to sulfate depletion than E. coli.
A remarkable property of M. tb is its ability to grow in cul-
ture with carbon monoxide (CO) serving as the sole car-
bon source [26,27]. Unlike other mycobacteria that can
grow with CO as the sole carbon source, M. tb lacks ribu-
lose-bisphosphate carboxylase (RuBisCO), an enzyme
found in plants enabling fixation of carbon dioxide.
Although it was argued that a reductive citric acid cycle
may enable the fixation of carbon dioxide into by M. tb
[27,28], experimentally it was observed that citrate did
not affect M. tb growth on CO [27]. We did not expect
iNJ661 to grow on CO, since the only experimentally
characterized CO associated metabolism in M. tb was CO
dehydrogenase (CODH). The uptake of glycerol versus
the uptake of CO while optimizing for growth can be seen
in Figure 3. CO uptake affects the biomass optimization
only during minimal uptake of glycerol, over a slight
range. The contribution being made in this region is the
donation of protons (through the oxidation of CO to
CO2). Looking further into this issue, we tested the
Table 1: The confidence level for each reaction is based on a 
scale from 0 to 4, 4 being the highest level of confidence 
(experimental biochemical evidence supporting the inclusion of a 
reaction) and 1 being the lowest level of confidence (inclusion of 
a reaction solely on modeling functionality). Sequence based 
annotations have a confidence level of 2.
Network properties of iNJ661
Genes 661
Proteins 543
Reactions (intra-system) 939
Reactions (exchange) 88
Gene Associated Reactions 77%
Metabolites 828
Average Confidence level 2.31Page 3 of 20
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(even though M. tb is not known to have it). We added
RuBisCO in addition ribose 1-phosphokinase and ribose
1,5-bisphosphate isomerase (to complete the pathway)
and optimized for growth on a modified Middlebrook
7H9 media (glycerol and glucose were removed and CO
was added). iNJ661 was unable to grow under these con-
ditions, despite conferring the ability to fix CO2 with
ribose sugars. This observation in conjunction with Figure
2a suggests that one possibility for how M. tb is able to
grow using CO as the carbon source is that it somehow is
able to fix CO into a glycolytic intermediate that does not
appear to occur through a RuBisCO pathway or a reduc-
tive citrate cycle.
A context for content
This BiGG reconstruction can be used as a 'context for
content' in analyzing large biological datasets. Multiple
investigators have employed high-throughput data analy-
sis methods to characterize M. tb in different environmen-
tal conditions, Sassetti et al [23] used transposon site
hybridization (TraSH) to identify the genes needed for
optimal growth of M. tb in vitro (this will be referred to as
the OptGro dataset throughout the rest of the text), Gao et
The Gene Index for Mycobacterium tuberculosis H37Rv was downloaded from The Institute for Genomic Research (TIGR) [45]Figur  1
The Gene Index for Mycobacterium tuberculosis H37Rv was downloaded from The Institute for Genomic Research (TIGR) 
[45]. Reconstruction content was defined based on the sequence annotation, legacy data, the Tuberculist database [31], ancil-
lary sources such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), and SEED [47]. Reactions were defined and 
according to the Tuberculist web and KEGG. Legacy data was also used in the process of building the model from the recon-
struction. The manual curation aspects of the reconstruction are outlined above and discussed in further detail in [42]. Debug-
ging was started once the first draft of the reconstruction was completed and functional testing (i.e. flux balance analysis 
calculations, etc.) were begun.
Reconstruction and Model Building of iNJ661 from M. tb H37Rv
iNJ661 Reconstruction
iNJ661 Model
Manual Curation Steps
Evidence for gene
Identify catalytic protein complex/subunits
Reaction definition:  primary metabolite conversion
Reaction definition:  secondary metabolites/cofactors
Metabolites:  formula and charge determination
Reaction definition:  catalytic mechanism
Reaction definition:  compartmentation
Confirm reaction mass conservation
Confirm reaction charge conservation
Manual Curation Resources
Primary Literature
Textbooks
Internet Resource Databases: Tuberculist, KEGG, SEED
Debugging
Identify gaps and carry out directed manual curation
Eliminate `free energy’ loops
Convert to Model
Define system boundaries and uptake constraints
Test anabolic and catabolic capabilities
Tuberculist
KEGG
The SEED
Genome Annotation (TIGR)Page 4 of 20
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BMC Systems Biology 2007, 1:26 http://www.biomedcentral.com/1752-0509/1/26Table 2: The list of biomass components for the initial biomass function. [See Additional file 1] for the additional components added 
for the extended biomass function and [see Additional file 5] for the explicit names and molecular formulas.
Biomass composition for growth of iNJ661
mmol/gDW Abbreviation
0.40596 ala-L
0.02261 cys-L
0.12031 asp-L
0.09001 glu-L
0.04810 phe-L
0.33581 gly
0.04062 his-L
0.08773 ile-L
0.03909 lys-L
0.20471 leu-L amino acids
0.03489 met-L
0.04770 asn-L
0.13803 pro-L
0.05812 gln-L
0.12042 arg-L
0.14340 ser-L
0.13571 thr-L
0.20583 val-L
0.02012 trp-L
0.03176 tyr-L
0.13903 amp
0.25095 cmp
0.24365 gmp
0.13160 ump nucleic acids
0.00349 damp
0.00666 dcmp
0.00666 dgmp
0.00365 dtmp
0.00797 tre
0.00118 tat
0.00125 pat
0.00114 sl1
0.00649 tre6p
0.00647 tres
0.16315 glc-D
0.09507 man sugars
0.02172 rib-D carbohydrates
0.05547 gal peptidoglycans
0.23018 acgam1p
0.00279 uamr
0.00101 uaaAgla
0.00101 uaaGgla
0.00099 uaagmda
0.00098 ugagmda
0.02536 glycPage 5 of 20
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0.01885 peptido_TB2
0.00073 arabinanagalfragund
0.00168 Ac1PIM1
0.00149 Ac1PIM2
0.00134 Ac1PIM3
0.00121 Ac1PIM4
0.00127 Ac2PIM2
0.00208 PIM1
0.00179 PIM2
0.00157 PIM3
0.00140 PIM4
0.00127 PIM5
0.00115 PIM6
0.00406 pe160
0.00586 clpn160190 fatty acids
0.01219 ttdca glycolipids
0.23515 hdca phospholipids
0.01094 hdcea
0.03484 ocdca
0.00985 ocdcea
0.09580 mocdca
0.01568 arach
0.00784 mbhn
0.05835 hexc
0.00724 pa160
0.00680 pa160190
0.00641 pa190190
0.00649 pg160
0.00613 pg160190
0.00581 pg190
0.01100 mycolate
0.00334 kmycolate
0.00329 mkmycolate
0.00337 mmmycolate
0.00111 tmha1 mycolic acids
0.00110 tmha2 phenolic glycolipids
0.00110 tmha3 mycocerosates
0.00110 tmha4 mycobactin
0.00645 phdca
0.00118 mfrrppdima
0.00140 mcbts
0.00150 fcmcbtt
0.00027 pdima
0.00026 ppdima
60.00000 atp
60.00000 adp (product) growth associated maintenance
60.00000 pi (product)
Table 2: The list of biomass components for the initial biomass function. [See Additional file 1] for the additional components added 
for the extended biomass function and [see Additional file 5] for the explicit names and molecular formulas. (Continued)Page 6 of 20
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expressed under different growth conditions in liquid cul-
ture (this will be referred to as the ConstExp dataset
throughout the rest of the text), and Sassetti in 2003 inves-
tigated the set of genes needed for M. tb survival in vivo
during infection in mice [30] (will be referred to as the
Infect dataset). The degree of overlap between the three
datasets can be seen in Figure 4A (only 2 genes are shared
by all three sets) highlight the variability of gene expres-
sion across the different experimental datasets. Although
significant differences between in vivo and in vitro patterns
of gene expression may be expected, the OptGro and Con-
stExp datasets were both done in vitro. The heterogeneity
among the datasets (all three experimental datasets share
only two loci) suggests that defining an objective function
based on in vitro data, may not necessarily translate to use-
ful results in vivo (it may constrain the solution space from
the wrong directions).
We evaluated these three datasets for M. tb and compared
them to gene deletion analyses for iNJ661, in which each
gene was individually deleted and growth was optimized
on Middlebrook media. Any growth rate that fell short of
the maximum wild type growth was considered 'sub-opti-
mal'. Table 5a summarizes the 114 false negative (iNJ661
gene non-essentiality, but in vitro gene essentiality; 50%)
results between iNJ661 and the OptGro dataset (for the
full results [see Additional file 4]). The inconsistencies
were considered individually and classified into four cate-
gories, Not in Objective Function (NOF), Alternate Route
(AR), Alternative Locus (AL), and Not Essential (NE);
these classifications are not mutually exclusive and were
defined in order to navigate and interpret with greater
ease. A gene was placed in the NOF category if it was iden-
tified to be in a biosynthetic pathway (based on network
connectivity) for a particular metabolite, such as a vitamin
or co-factor. Genes would be categorized as AR or AL if
there was an alternative biochemical route or an alterna-
tive gene annotation that could carry out that reaction in
iNJ661, respectively, but not in M. tb. Potential AR or AL
classifications reflect one of the potential errors due to
sequence based annotations, so further biochemical char-
acterization of the gene products would help resolve these
cases. Genes that did not fall in these categories were clas-
Table 4: Summary of iNJ661 biomass production rates (in mmol/hr/g dwt) and doubling times (1/hr) in silico on different media. * from 
[19], ^ from [18].
iNJ661 Growth
Biomass Accumulation iNJ661 Doubling Time M. tb Doubling Time
Middlebrook 7H9 0.052 13.33
Youman's 0.029 23.90 24*
CAMR 0.058 11.95 14.7^
Table 3: *Glucose and glycerol supplementation were added as described in [20].
in silico media composition
Youmans Middlebrook 7H9 CAMR
oxygen ammonium L-alanine
L-asparagine calcium L-arginine
citrate chloride L-asparagine
glycerol citrate L-aspartic acid
water copper L-glutamic acid
octadecanoate (Tween) ferric iron L-glycine
phosphate L-glutamate L-isoleucine
sulfate magnesium L-leucine
magnesium oxygen L-serine
potassium phosphate L-phenylalanine
bicarbonate sodium pyruvate
(ferric iron: minimal amount) sulfate glycerol
water octadecanoate (Tween)
D-glucose*
glycerol*Page 7 of 20
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in which the flux variability was uniformly zero (maxi-
mum and minimum value).
Since quantitative data was not available for vitamins and
cofactors, they were not included in the original defini-
tion of the objective function (Table 2). However, after the
deletion analysis, the majority of the false negative predic-
tions in the NE category by iNJ661 were reactions associ-
ated with the biosynthesis of vitamins and cofactors, such
as dihydrofolate and tetrahydrofolate. 16 such metabo-
lites were added [see Additional file 1] to the biomass
function with coefficients of 0.000001 (small enough to
have negligible effects on quantitative growth, but still
required for growth). The results for the genes required for
optimal growth using the initial biomass function and the
expanded compared to OptGrow are displayed in the first
Venn diagram of Figure 4B. Although only 16 metabolites
were added, the deletion study resulted in 31 more gene
loci that matched the OptGro data. This only slightly
increased the deletion prediction from 54% to 56%. The
reason for the modest increase is that there were also 18
additional false positive (iNJ661 gene essentiality, but in
vitro gene non-essentiality) results (from 46% to 44% for
the original and expanded objective functions, respec-
tively).
Genes categorized as AL or AR suggest that there was an
error in the sequence based annotation, there are regula-
tory control loops that we are not aware of, or there was a
false positive result from the experimental data (TraSH is
often used as a screening tool). Sassetti et al [23] dicussed
one of these cases involving the Rv0505c and Rv3042c
loci (serB and serB2 respectively). Both have been
assigned the same function based on annotation, however
serB2 was found to be essential while serB was not. There
may be many possibilities why serB cannot rescue muta-
tions/deletions of serB2, however the detection of such
cases imply that having duplicate genes many not confer
the degree or robustness that is often assumed to accom-
pany an organism. The cases with alternative loci high-
light areas where further experimental investigation may
provide insight into the growth capabilities of M. tb. The
AL cases are enumerated in Table 5b. These loci are worth
further experimental investigation to confirm the annota-
tion and to determine the different conditions which may
induce or inhibit expression. The false negative prediction
for the sulfate transporter (Rv2397c, Rv2398c, Rv2399c,
and Rv2400c) is an interesting case to consider, in part
because it validates the observations in the phase plane
discussed in Figure 2b. Additionally, it identifies an area
in which a partially characterized annotation causes erro-
neous results. The four aforementioned loci form a pro-
tein complex in the model in order to catalyze the
a. Phase plane diagram of glycerol versus glucose uptake while optimizing for growth on Middlebrook mediaFigure 2
a. Phase plane diagram of glycerol versus glucose uptake while optimizing for growth on Middlebrook media. iNJ661 can grow 
with glycerol serving as the sole carbon source, but not glucose. The open dots are the calculated phase points and the solid 
black lines indicate isoclines. b. Phase plane diagram for phosphate versus sulfate uptake on Middlebrook media. Although the 
transport fluxes are very small, they are both necessary for the organism to be able to grow.Page 8 of 20
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annotation identifying Rv1739c as a sulfate transporter
[31], an association was made between Rv1739c in addi-
tion to the existing protein complex (Rv2397c + Rv2398c
+ Rv2399c + Rv2400c). So, although the sulfate trans-
porter is essential for in silico growth of iNJ661, the lack of
a biochemically characterized gene protein relationship
can result in false predictions.
The 103 false positive cases likely reflect incomplete
knowledge about the network (alternative pathways exist)
or an alternative objective function [see Additional file 4].
Approximately 20 cases involve amino acid pathways,
since amino acids would presumably be required for any
kind of growth in lab conditions, these cases likely suggest
alternative pathways or enzymes are present in M. tb that
are not in iNJ661. Almost half of these cases (46) involve
fatty acid, membrane, or peptidoglycan metabolism, since
the fatty acid composition in M. tb can change signifi-
cantly over time in vitro [9], many of these false predic-
tions are likely to be due to changes in the biomass
composition (in silico simulations have fixed biomass
compositions). These cases highlight areas in which
experimental studies documenting the changes in compo-
sition and growth rates may yield interesting results. Five
of the cases involve loci associated with the transport of
phosphate, ammonium, and a sugar transporter. These
cases likely involve as of yet unidentified alternative trans-
porters in M. tb. Another case involves glycerol kinase
(Rv3696c, GlpK, GLYK) which was one of the fluxes with
no flexibility (see M. tb growth in silico), since M. tb in
vitro requires glycerol supplementation for growth [20].
However, since glycerol kinase does not appear to be
required even for sub-optimal growth as implied by the
OptGro dataset, there must be other reactions involving
the direct metabolism of glycerol that have not yet been
identified for M. tb. The ability to grow using CO as the
sole carbon source and maintain optimal growth even
without glycerol kinase activity imply unique and uniden-
tified aspects to central metabolism in the M. tb network.
Biomass optimization on Middlebrook media without glucoseF gure 3
Biomass optimization on Middlebrook media without glucose. Carbon monoxide uptake can affect the growth at very low glyc-
erol uptake rates via Carbon Monoxide Dehydrogenase, which generate protons through the oxidation of carbon dioxide.Page 9 of 20
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BMC Systems Biology 2007, 1:26 http://www.biomedcentral.com/1752-0509/1/26Further experimental investigations may provide clues
towards controlling the growth of M. tb (increasing the
growth rate in culture and inhibiting growth in vivo).
Out of the 194 genes identified in the Infect dataset, only
17 were shared with the OptGro dataset and 37 were
shared with the ConstExp dataset (Figure 4A). From these
three sets of experimental datasets, OptGro and ConstExp
had the greatest number of genes in common, 162. How-
ever this is still only about 27% and 29% of the genes in
each dataset, respectively. The large variability between all
of these datasets highlights the point that further develop-
Summary of experimental datasets and their overlap with iNJ661 and the iNJ661 gene deletion studiesFigure 4
Summary of experimental datasets and their overlap with iNJ661 and the iNJ661 gene deletion studies. OptGro refers to the 
dataset described in [23], ConstExp refers to the dataset described in [29], and Infect describes the dataset in [30]. ^ denotes 
the subset of genes from the experimental dataset contained in iNJ661. iNJ661 represents the 661 genes in the reconstruction. 
iNJ661 optimal growth represents the subset of genes required for optimal growth with the original objective function. iNJ661 
optimal growth* represents the subset of genes required for optimal growth with the objective function expanded to include 
vitamins and cofactors. iNJ661 alternative objective represents the set of genes required for optimal growth using the objective 
function constructed based on the ConstExp dataset. Panel A: The Venn diagram shows the overlap between the different 
experimental gene expression datasets. The accompanying chart summarizes the total number of genes in each dataset and 
how many of those genes are found in the iNJ661 reconstruction. Panel B: Series of Venn diagrams summarizing the results for 
the gene deletion studies carried out of iNJ661 compared to the experimental gene expression datasets.
iNJ661
optimal
growth
OptGro^
310
31
18
83
123
iNJ661
optimal
growth*
iNJ661
optimal
growth 019
10
39
55
36
iNJ661
optimal
growth*
ConstExp^
iNJ661
optimal
growth 421
3
46
20
12
iNJ661
optimal
growth*
Infect^
OptGro ConstExp
Infect
5315
437 363
142
2
160
A
B
OptGro ConstExp Infect
Genes in Data Set 614 560 194
Genes Shared with iNJ661 237 101 103
Table 5a: Classification of False Negative results by subdivision into four overlapping categories for the gene deletion study in iNJ661 
compared to the OptGro dataset. Each row and column lists the number of those genes in the respectively classes. NOF: Not in 
Objective Function, AR: Alternate Route, AL: Alternative Locus, NE: Not essential.
Classification of False Negative results
AL AR NE NOF
AL 26 0 5 2
AR 0 7 6 1
NE 5 6 24 0
NOF 2 1 0 43Page 10 of 20
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BMC Systems Biology 2007, 1:26 http://www.biomedcentral.com/1752-0509/1/26ment of Flux Balance Analysis based approaches will
require the definition alternative objective functions to
biomass optimization.
Functional assessment independent of objective functions
Biomass functions can help improve predictions under
well-defined conditions by constraining the steady state
solution space. However, different growth conditions can
appreciably alter the composition and the 'objectives' of
bacteria, as reflect by Figure 4A and the discussion above.
Significant changes in fatty acid composition have been
observed even while growing M. tb in culture over the
span of weeks [12]. These changes would be reflected as
changes in the composition and the coefficients of the
biomass function, consequently altering the predictions
made by the model. Not all COBRA methods require the
definition of objective functions [32] and identifying
groups of reactions that operate together can help simplify
a network and provide insight into its functionality [33].
Correlated reaction sets have been calculated using sam-
pling [34] and flux coupling [35] and implications for
classifying diseases and identifying pathway specific drug
targets have been discussed [36]. Applying the same sys-
tems view of metabolic networks to pathogens such as M.
tb causes one to adopt the view that single enzyme drug
targets actually knock out complete pathways. As a result,
terminating the activity of any other enzyme in that path-
way should have the same effect. Similar to the correlated
Table 5b: Detailed listing of the AL results for the False Negative results for iNJ661. The first column lists a locus needed for optimal 
growth according to the OptGro dataset. The second column lists the reactions involved. The third column lists the possible 
alternative loci in iNJ661 (commas indicate isozymes, addition symbols indicate formation of protein complexes).
Alternative Loci in False Negative results
OptGro Reaction Other loci in iNJ661
Rv0337c ASPTA Rv2565
Rv0462 PDHc, PDH, PDHa Rv0843, Rv2497c+Rv2496c
Rv0808 GLUPRT Rv1602
Rv0824c DESAT18 Rv1094
Rv1122 GND Rv1844c
Rv1600 HSTPT Rv3772, Rv2231c
Rv1602 GLUPRT Rv0808
Rv1609 ANS Rv2859c
Rv2182c AGPAT160190, AGPAT160, AGPAT190 Rv2483c
Rv2215 PDH, AKGDb Rv2241, Rv0462, Rv0843
Rv2231c HSTPT Rv1600, Rv3772
Rv2397c SULabc, TSULabc Rv1739c
Rv2398c SULabc, TSULabc Rv1739c
Rv2399c SULabc, TSULabc Rv1739c
Rv2400c SULabc, TSULabc Rv1739c
Rv2682c DXPS Rv3379c
Rv2746c PGSA190, PGSA160, PGSA160190 Rv1822
Rv2996c PGCD Rv0728c
Rv3003c ACLS Rv3509c+Rv3002c, Rv1820+Rv3002c, 
Rv3509c+Rv3002c, Rv3002c+Rv3470c
Rv3042c PSP_L Rv0505c
Rv3257c PMANM, AIRCr Rv3275c+Rv3276c
Rv3275c AIRCr Rv3257c+Rv3276c
Rv3281 ACCOACr Rv3280+Rv0904c
Rv3441c PMANM, ACGAMPM Rv3308, Rv3257c
Rv3634c UDPG4E Rv0536, Rv0501
Rv0112 GMAND Rv1511
Rv2247 PPCOAC Rv2502c+Rv0973c, Rv3285+Rv0974c, 
Rv0973c+Rv0974c,
Rv0973c PPCOAC Rv2502c+Rv0973c, Rv3285+Rv0974c, 
Rv0973c+Rv0974c, Rv2501c+Rv2247
Rv3285 PPCOAC Rv2502c+Rv0973c, Rv0973c+Rv0974c, 
Rv2501c+Rv2247
Rv2967c PC Rv2976c
Rv3464 TDPGDH Rv3468c, Rv3784
Rv2754c TMDS Rv2764c
Rv3713 ADCYRS Rv2848cPage 11 of 20
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sets are defined by mass balance constraints. The defini-
tion of HCRs is stricter in the sense that it is based on
metabolites with one-to-one connectivity. However in
contrast to the other approaches, it is independent of the
exchange reactions with the environment and any require-
ments for demand functions. Consequently, the sets can
be calculated directly from the stoichiometric matrix.
There is a significant degree of overlap between HCRs and
the Enzyme Subsets (ES) described by Pfeiffer et al [37].
Since ESs are not constrained by 1:1 connectivity, in prin-
ciple they may include additional reactions. On the same
token, when the same reaction is carried out by multiple
co-factors and the reactions are reversible, which is not
uncommon in metabolic networks, ESs may add reactions
which form loops (similar to Type III Extreme Pathways
[38]). Additionally, intermediate steps in the calculation
of HCRs allow the consideration of inclusion or removal
of potentially reversible reactions.
147 HCR sets (1:1 only, additional reversible reactions,
0:2/2:0, were not included, see Methods) were calculated
for the network, the average size of each set was 2.93, with
median and modes both equal to 2. The largest set, HCR
40, consisted of 13 reactions involved in Cofactor Metab-
olism and Porphyrin Metabolism. The summary of how
the HCRs are split among the 35 subsystems in the net-
work are outlined in Table 6. Using the Gene-Protein-
Table 6: HCR sets mapped to the subsystems in the network along with the size of each subsystem.
HCR mapping to subsystems
Metabolic Subsystem HCR Sets in each Subsystem Number of HCRs
Alanine and Aspartate Metabolism 47,81,99,126 4
Arginine and Proline Metabolism 126 1
Biotin Metabolism 33 1
Citric Acid Cycle 98 1
Cofactor Metabolism 7,24,25,26,30,40,56,77,118,123,129 11
Cysteine Metabolism 38 1
Fatty Acid Metabolism 1,43,57,78,86,90,93,94,95,96,97,103,108,110,11
4,115,116,128,132
19
Folate Metabolism 9,22,28,31,44 5
Glutamate Metabolism 21,27,29,67,76 5
Glycine Serine Threonine Metabolism 19,24,45,111,124 5
Glycolysis 41,42 2
Glyoxylate Metabolism 104 1
Histidine Metabolism 10,70 2
Lysine Metabolism 2,8 2
Membrane Metabolism 23,29,34,35,36,43,46,61,64,65,66,74,79,97,103,
106,107,108,109,110,112,113,116,117,130,131,
138
27
Methionine Metabolism 27,28,45,91,92 5
Nucleotide Sugar Metabolism 55,59,63,69,75,83,140 7
Other Amino Acid Metabolism 29,48,82,91,92,125,127 7
Pantothenate and CoA Metabolism 12,67,68,81 4
Pentose Phosphate Pathway 32,121 2
Peptidoglycan Metabolism 43,133,134,136,137,100 6
Phenylalanine Tyrosine Tryptophan Metabolism 10,11,20,85,105 5
Polyprenyl Metabolism 16,60,62,77 4
Porphyrin Metabolism 25,30,40,51,52,53 6
Purine Metabolism 5,17,27,49,58,63,73,140 8
Pyrimidine Metabolism 55,59,83,98 4
Pyruvate Metabolism 82 1
Redox Metabolism 39,50,71,72,76,80,100,102 8
Riboflavin Metabolism 6,7,26,30,56 5
Sugar Metabolism 15,42,74,75,87,89,99,119,120,135 10
Thiamine Metabolism 15 1
Transport 39,48,54,71,82,84,87,88,89,101,102,106,110,12
4,127,139,141,142,143,144,145,146,147
23
Ubiquinone Metabolism 13,122,125 3
Urea Cycle 27,37 2
Valine Leucine Isoleucine Metabolism 3,4,14,18,84,88,139 7Page 12 of 20
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BMC Systems Biology 2007, 1:26 http://www.biomedcentral.com/1752-0509/1/26Reaction relationships which form the foundation of the
reconstruction, we mapped the HCRs back to the gene loci
(Figure 5). The complete HCR set mapped to 124 loci and
61 HCRs in the OptGro dataset, to 46 loci and 34 HCRs
in the ConstExp dataset, and 21 loci and 18 HCRs in the
Infect dataset [see Additional file 2]. The OptGro and
ConstExp shared 8 HCR sets (HCR 2, 3, 11, 12, 43, 57, 69,
and 122). The intersection of these datasets identifies a
subset of reactions that are consistently expressed under
different conditions and also required for optimal growth
in vitro. These HCR sets may reflect underlying core sets of
reactions vital to growth and survival in vitro.
Many of the tuberculosis treatment drugs have metabolic
targets [1] and a use of this metabolic based reconstruc-
tion can be to assist in identifying new and alternative
chemotherapy targets for tuberculosis. Mdluli and Spigel-
man recently discussed the drug targets in M. tb reasona-
bly comprehensively [39]. We used the list (absent the
DNA synthesis and Regulatory Protein targets) and
mapped them to the 147 HCR sets as seen in Table 7 [see
Additional file 3 for the full set]. The final column lists the
number of different reactions in the HCR. Other reactions
that are shared within a particular HCR which contains a
known drug target, have the potential to be alternative but
The stoichiometric matrix is created from the metabolic networkFigure 5
The stoichiometric matrix is created from the metabolic network. The HCR (Hard Coupled Reaction) sets are calculated 
directly from the stoichiometric matrix and mapped back to the gene loci. Gene-Protein-Reaction relationships: top box is the 
gene, the next box is the peptide, the oval represents the functional protein, and the bottom boxes are the reactions catalyzed 
by the protein.
Calculating Hard Coupling Reaction Sets 
and Mapping to Genes
Stoichiometric Matrix
Metabolic Network
Rv0211
pckA
PckA
PEPCK_re PPCKr
Gene-Protein-Reaction
Association
Transcript
Catalyzed 
Reaction
Protein
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Hard Coupled 
Reaction Sets
Gene
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Table 7: Mapping the HCR sets to the drug targets described by Mdluli and Spigelman [39]. The first column includes the protein 
names (adopted from Mdluli and Spigelman), the second column lists the corresponding gene locus, the third is the HCR set number 
and the fourth lists how many reactions are in the HCR set. Only those drug targets mapped to an HCR are shown. [See Additional file 
3] for the full set of HCR sets and the individual reactions they are comprised of; the HCR sets mapped to the above drug targets are 
highlighted in these data.
HCRs mapped to Mtb drug targets
Drug Target Gene Locus HCR HCR size
EmbA Rv3794 43 10
EmbB Rv3795 43 10
EmbC Rv3793 43 10
AftA Rv3792 43 10
decaprenyl phosphoryltransferase Rv3806c 62 3
udp galatofuraosyltransferase Rv3808c 43 10
dTDP-deoxy-hexulose reductase Rv3809c 43 10
RmlA Rv0334 69 4
RmlB Rv3464 69 4
RmlC Rv3465 69 4
RmbD Rv3266c 69 4
InhA Rv1484 57 3
MabA Rv1483 90 5
KasA Rv2245 90 5
KasB Rv2246 90 5
MmaA4 Rv0642c 93 4
Pks13 Rv3800c 86 4
FadD32 Rv3801c 86 4
AccD5 Rv3280 78 2
LeuD Rv2987c 14 2
TrpD Rv2192c 10 4
DapB Rv2773c 2 3
AroA Rv3227 20 3
AroC Rv2540c 20 3
AroE Rv2537c 11 4
AroG Rv2178c 11 4
AroQ Rv2537c 11 4
ilvG (acetolactate synthase) Rv1820 3 3
ilvX (acetolactate synthase) Rv3509c 3 3
ilvN (acetolactate synthase) Rv3002c 3 3
ilvB (acetolactate synthase) Rv3003c 3 3
ilvB2 (acetolactate synthase) Rv3470c 3 3
branchd chain aminotransferase Rv2210c 84 2
dihyropteroate synthase Rv3608c 9 3
dihyropteroate synthase Rv1207 9 3
PanC Rv3602c 12 4
riboflavin synthase Rv1416 56 3
riboflavin synthase Rv1412 56 3
sulfotransferase Rv1373 131 2
MshA Rv0486 80 2
MshB Rv1170 80 2
MshC Rv2130c 50 2
MshD Rv0819 50 2
IspD Rv3582c 16 5
IspE Rv1011 16 5
IspF Rv3581c 16 5
MenA Rv0534c 13 2
MenB Rv0548c 122 3
MenD Rv0555 125 2
MenE Rv0542c 122 3
BMC Systems Biology 2007, 1:26 http://www.biomedcentral.com/1752-0509/1/26metabolically equivalent targets. The drug targets mapped
to 25 of the HCR sets. These sets are depicted on a reduced
metabolic map of iNJ661 (Figure 6). An image of the HCR
sets mapped to the entire metabolic network will be avail-
able on our website [40]. These 25 HCR sets contain all of
the 8 HCR sets identified by the overlap between the Opt-
Gro and ConstExp data.
Last year Raman et al [41] constructed and analyzed a
model of the mycolic acid synthesis pathways and pro-
posed additional targets in fatty acid metabolism.
Accounting for the entire metabolic network further
builds upon this by enabling a more rigorous evaluation
of the global growth capabilities of the network and the
identification of potential drug targets. The genome-scale
model presented here includes the extensive fatty acid
metabolism pathways of M. tb, in addition to rest of the
metabolic network. With this full network, we then
sought to extend the identification of potential drug tar-
gets by taking advantage of the underlying principles of
reconstructing metabolic networks to calculate HCR sets.
Interpreting large, complex networks in a functionally
meaningful manner is enabled by adopting a hierarchical
view of the network, where one identifies groups of reac-
tions that respond in unison to changes in media condi-
tions. Groups of reactions strictly bound together based
on mass conservation and stoichiometry constraints can
lead to the definition of hierarchical sets of reactions
[33,34]. This principle was applied to causal SNP associ-
ated diseases in the human mitochondria, and it was
found that reactions in the same co-set had similar disease
A partial metabolic map of iNJ661 with the 25 drug target HCR setsFigu e 6
A partial metabolic map of iNJ661 with the 25 drug target HCR sets. Each reaction is numbered and color coded according to 
the HCR which it belongs to. The number of the HCR sets matches those in the Additional files. Only pathways or parts of 
pathways which included members of the 25 HCRs are depicted.
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but rather than looking for disease phenotypes, we sought
to identify alternative drug targets.
Conclusion
Over time and with iterative improvements, metabolic
network reconstructions have achieved the stage of
hypothesis generation and model-driven biological dis-
covery in systems biology [42]. We present an in silico
strain of M. tb, iNJ661, with the anticipation that it will be
received by the community in a similar vein and to assist
in the discovery process of this remarkable yet devastating
pathogen.
A large amount of material has been presented in this
manuscript, beginning with the presentation of a genome-
scale reconstruction and model of M. tb, iNJ661, followed
by experimental validation and use of the model for inte-
gration and analysis of multiple experimental datasets.
We summarize some of the main points that highlight
areas in which further experimental research may be fruit-
ful.
Growth studies
• iNJ661 can grow at rates consistent with experimental
data in varying media conditions. Further measurements
of the biomass composition of M. tb in well-defined situ-
ations are likely to improve the in silico predictions under
those conditions.
• Analysis of the capabilities under maximal growth con-
ditions can help identify critical nutrient targets for killing
M. tb (such as the sulfate transporter) or for optimizing
growth (in the lab).
• The pathway enabling growth of M. tb using CO as the
carbon source is still unclear. The computational studies
suggest that there must be an alternative pathway (to
reductive citrate cycle and RuBisCO) which enables entry
of CO2 into central metabolism.
• The seemingly paradoxical need for glucose supplemen-
tation in Middlebrook media but non-essentiality of
directly related reactions involving the metabolism of glu-
cose-6-phosphate for in vitro growth and the almost dia-
metrically opposed results for in silico growth, suggest that
there may be additional pathways involving glucose
metabolism and potentially non-metabolic functions
related to the glucose requirement.
Comparison with and analysis of large datasets
• The definition of the biomass function will largely dic-
tate the results of optimal growth/gene deletion experi-
ments, consequently, positive results (in agreement with
the experiments) are not as interesting as the false negative
(or false positive results). The false negative results may be
due to an error in the annotation of the gene or an under-
lying physiological mechanism that we are not aware of.
In either case, investigating the particular genes experi-
mentally may help clarify the issue.
• The model can be used as a Context for Biological Con-
tent and provides a consistent, coherent framework to
analyze various datasets focusing on metabolism.
'Unbiased' analysis
Unbiased analysis methods, methods that calculate prop-
erties of the network independent of objective functions,
can provide interesting and valuable insights into network
capabilities [32]. The definition of HCR sets, in a similar
vein to correlated reaction sets from sampling and flux-
coupling, can confer a hierarchical structure to metabolic
networks, and may assist in the identification of alterna-
tive drug targets. Using these models in conjunction with
experimental data can assist in screening and identifying
new and alternative drug targets.
Taken together, this study adds another high resolution
reconstruction of microbial metabolism. There now exist
a growing number of such reconstructions that have been
particularly useful for basic studies of network properties
and for bioprocessing applications [42-44]. As the
number of reconstructions of human pathogens grows,
we should be able to expand their uses towards improved
understanding pathogenic mechamisms, and design of
interventions and treatment. Large-scale rigorous experi-
mental validation studies should now be performed to
further these goals.
Methods
Reconstruction and model development of the metabolic
network has been described previously [7,8]. The recon-
struction contents will be made available on our website
[40]  in Excel [see Additional file 5] and SBML formats.
Reconstruction
Figure 1 provides a brief summary of the reconstruction
and modeling building process. The sequence based
genome annotation of Mycobacterium tuberculosis
H37Rv was downloaded from TIGR [45] and served as the
framework of the model. Charge and elementally bal-
anced reactions were added individually based on this
annotation, legacy data when available, and updates
made in the Tuberculist database [31]. KEGG [46] and the
SEED [47] were used as ancillary tools on occasion. Fol-
lowing the initial reconstruction, the gaps were evaluated
individually by searching for direct evidence in the litera-
ture for their metabolism. Due to the relative sparsity of
literature on aspects of central and cofactor metabolism in
M. tuberculosis, many of these gaps could not be filled. Leg-Page 16 of 20
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and textbooks were employed in addition to the database
resources [see Additional file 6] during the reconstruction
and model building phases. A comprehensive map of
iNJ661's metabolic network was visualized by creating a
map of the network organized by lumped subsystems of
metabolism [see Additional files 8, 9, 10, 11, 12, 13, 14,
15]. After the debugging process, when the cell could grow
(i.e. produce biomass) on different media, the remaining
intracellular gaps were evaluated by searching the litera-
ture for evidence of metabolic reactions involving that
particular metabolite. If no evidence of transport or bio-
chemical transformations of the metabolite in M. tb was
found, no additional reactions or transporters were
added.
Model formulation
The stoichiometric matrix, S, was constructed based on
the reactions described in the reconstruction. The biomass
function was defined using available legacy data [see
Additional file 1]. Flux Balance Analysis (FBA) simula-
tions were employed during the debugging process
towards developing a functional model.
Flux Balance Analysis (FBA)
The metabolic network is represented mathematically by
the stoichiometric matrix, m rows by n columns, where
there are m metabolites and n reactions in the network.
Mass conservation dictates
which simplifies to
S·v = 0
at the steady state. Further constraints can be placed on
the system based on thermodynamics (reaction direction-
ality) and limits on substrate uptake rates
α ≤ v ≤ β
The oxygen uptake rate measured from the Mycobacteria
Bovis BCG strain of 25 μL/hr/mg dry weight (0.98 mmol
O2/hr/g dry weight) [48] was used. The small molecule
carbon sources (glucose, glycerol, etc.) were limited to an
uptake rate of 1 mmol/hr/g dry weight and all other
allowable substrates were unconstrained. The different in
silico culture media are listed in Table 3. Deviations from
the standard media include: the addition of minute
amounts of ferric iron in Youmans media. The oxygen
uptake rate was the growth constraining flux in all of the
different media.
Flux Variability Analysis (FVA)
Constraining the biomass objective function, c, to the
optimal value calculated in FBA,
max(cT·v)
every flux in the network is then minimized and maxi-
mized. The different between the maximum and mini-
mum for each flux defines the flux variability for that
reaction.
Robustness Analysis
Robustness plots are performed by varying a particular
flux through a pre-defined range and recalculating the
objective function. The slope of the curve describes the
sensitivity of the objective function on that particular flux
(over the specified range of values).
Hard-Coupled Reaction (HCR) Sets
Denoting the binary form of the stoichiometric matrix, ,
the input/reactant part of the stoichiometric matrix, S-,
and the output/product part of the stoichiometric matrix,
S+, then it is transparent that,
The input and output connectivities of each metabolite
can be calculated for - and +, respectively. The
input:output ratio for each metabolite can be determined
and all metabolites with 1:1 connectivity will be hard-
coupled by the network. Metabolites with 0:2 or 2:0 con-
nectivity reflect metabolites that are hard-coupled in the
event that the corresponding reaction is reversible. Metab-
olites with 0:1 or 1:0 connectivity are either source/sink
transporters or blocked reactions.
A general algorithm for calculating hard coupled reaction
sets.
1. Identify 1:1, 0:2, and 2:0 metabolites
2. Define HCRs
a. Identify the sets of reactions corresponding to the
metabolites, denote the entire set as HCR0
b. Join any HCR0 subset that share 1 or more reactions,
denote the entire set as HCR1
c. i ← 1
3. while (HCRi-1 ≠ HCRi)
dx
dt
S v= •
Sˆ
S S S= +
− +
ˆ ˆ
Sˆ SˆPage 17 of 20
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b. i ← i+1
Since 0:2 or 2:0 reactions may be irreversible reactions, an
intermediate processing step may be needed to verify that
there is biological evidence supporting the catalysis of the
reaction in the reverse direction. If one does not wish to
consider these potential effects and assume that all of the
reactions are reversible then step 1 can be simplified by
finding all of the 2 metabolites for . Biomass functions
were removed from the stoichiometric matrix before cal-
culating the HCR sets. The HCRs calculated for iNJ661
had 94 0:2/2:0 reactions. Of these, 24 overlapped with the
core set of 147 1:1 HCRs. Since the set of 0:2/2:0 reactions
did not have additional gene associations (that weren't
already in the 1:1 set) and since they had many irreversi-
ble reactions throughout, the 1:1 set and the 0:2/2:0 set
were not combined (step 1 in the above algorithm outline
would involve only identifying the 1:1 metabolites).
The reconstruction process, the metabolic maps, and the
majority of the calculations were performed using Sim-
pheny™ v1.11 software (Genomatica, Inc.). HCR Sets were
calculated with Mathematica© v4.2 (Wolfram Research,
Inc.).
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Molecular composition of biomass functions. A detailed list of the biomass 
constituents and their respective coefficients in the biomass function in 
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Click here for file
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Additional File 2
HCRs mapped to experimental data sets. The list of HCRs that mapped to 
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Additional File 3
HCRs mapped to reaction and metabolic subsystems. The complete list of 
HCRs, highlighting those known to be drug targets in M. tb.
Click here for file
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Additional File 4
Comprehensive list of false negatives between OptGro data set and 
iNJ661 lethal gene deletions. A catalog of the false negative results pro-
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